• Something wrong with this record ?

Evaluation of age at symptom onset, proband status, and sex as predictors of disease severity in pediatric catecholaminergic polymorphic ventricular tachycardia

D. Kallas, TM. Roston, S. Franciosi, L. Brett, KVV. Lieve, SY. Kwok, PJ. Kannankeril, AD. Krahn, MJ. LaPage, S. Etheridge, A. Hill, C. Johnsrude, J. Perry, L. Knight, P. Fischbach, S. Balaji, S. Tisma-Dupanovic, I. Law, J. Atallah, D. Backhoff,...

. 2021 ; 18 (11) : 1825-1832. [pub] 20210729

Language English Country United States

Document type Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc22011986

BACKGROUND: Children with catecholaminergic polymorphic ventricular tachycardia (CPVT) are at risk for sudden death, and a risk stratification tool does not exist. OBJECTIVE: The purpose of this study was to determine whether proband status, age at symptom onset, and/or sex are independent predictors of cardiac events. METHODS: A multicenter, ambispective, cohort of pediatric CPVT patients was categorized by sex, proband status, and age at symptom onset (D1: first decade of life [symptom onset <10 years] or D2: second decade of life [symptom onset 10-18 years, inclusive]). Demographics, therapy, genetics, and outcomes were compared between groups. RESULTS: A total of 133 patients were included and stratified into 58 D1 and 75 D2 patients (68 female and 65 male; 106 probands and 27 relatives). Localization of RYR2 variants to hotspots differed based on proband status and age at symptom onset. The cardiac event rate was 33% (n = 44/133), inclusive of a 3% (n = 4/133) mortality rate, over a median of 6 years (interquartile range 3-11) after time of symptom onset. Proband status, rather than age at of symptom onset or sex, was an independent predictor of time to first cardiac event (P = .008; hazard ratio = 4.4). The 5-, 10- and 15-year event-free survival rates for probands were 77%, 56%, and 46%, respectively, and for relatives were 96%, 91%, and 86%, respectively. Event risk after diagnosis was 48% (32/67) in patients on β-blocker or flecainide alone vs 10% (5/48) in patients on β-blocker plus flecainide and/or left cardiac sympathetic denervation (P <.001). CONCLUSION: Proband status, but not age at symptom onset or male sex, independently predicted an earlier onset of cardiac events. A larger sample size would enable a comprehensive investigation of other risk factors.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22011986
003      
CZ-PrNML
005      
20220506130624.0
007      
ta
008      
220425s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.hrthm.2021.07.061 $2 doi
035    __
$a (PubMed)34333088
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kallas, Dania $u BC Children's Hospital, Vancouver, Canada
245    10
$a Evaluation of age at symptom onset, proband status, and sex as predictors of disease severity in pediatric catecholaminergic polymorphic ventricular tachycardia / $c D. Kallas, TM. Roston, S. Franciosi, L. Brett, KVV. Lieve, SY. Kwok, PJ. Kannankeril, AD. Krahn, MJ. LaPage, S. Etheridge, A. Hill, C. Johnsrude, J. Perry, L. Knight, P. Fischbach, S. Balaji, S. Tisma-Dupanovic, I. Law, J. Atallah, D. Backhoff, A. Kamp, P. Kubus, A. Kean, PF. Aziz, J. Kovach, Y. Lau, J. Kron, SA. Clur, G. Sarquella-Brugada, AAM. Wilde, S. Sanatani
520    9_
$a BACKGROUND: Children with catecholaminergic polymorphic ventricular tachycardia (CPVT) are at risk for sudden death, and a risk stratification tool does not exist. OBJECTIVE: The purpose of this study was to determine whether proband status, age at symptom onset, and/or sex are independent predictors of cardiac events. METHODS: A multicenter, ambispective, cohort of pediatric CPVT patients was categorized by sex, proband status, and age at symptom onset (D1: first decade of life [symptom onset <10 years] or D2: second decade of life [symptom onset 10-18 years, inclusive]). Demographics, therapy, genetics, and outcomes were compared between groups. RESULTS: A total of 133 patients were included and stratified into 58 D1 and 75 D2 patients (68 female and 65 male; 106 probands and 27 relatives). Localization of RYR2 variants to hotspots differed based on proband status and age at symptom onset. The cardiac event rate was 33% (n = 44/133), inclusive of a 3% (n = 4/133) mortality rate, over a median of 6 years (interquartile range 3-11) after time of symptom onset. Proband status, rather than age at of symptom onset or sex, was an independent predictor of time to first cardiac event (P = .008; hazard ratio = 4.4). The 5-, 10- and 15-year event-free survival rates for probands were 77%, 56%, and 46%, respectively, and for relatives were 96%, 91%, and 86%, respectively. Event risk after diagnosis was 48% (32/67) in patients on β-blocker or flecainide alone vs 10% (5/48) in patients on β-blocker plus flecainide and/or left cardiac sympathetic denervation (P <.001). CONCLUSION: Proband status, but not age at symptom onset or male sex, independently predicted an earlier onset of cardiac events. A larger sample size would enable a comprehensive investigation of other risk factors.
650    _2
$a mladiství $7 D000293
650    _2
$a věk při počátku nemoci $7 D017668
650    _2
$a dítě $7 D002648
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a rizikové faktory $7 D012307
650    _2
$a stupeň závažnosti nemoci $7 D012720
650    _2
$a sexuální faktory $7 D012737
650    _2
$a komorová tachykardie $x epidemiologie $x terapie $7 D017180
651    _2
$a Kanada $x epidemiologie $7 D002170
651    _2
$a Spojené státy americké $x epidemiologie $7 D014481
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Roston, Thomas M $u BC Children's Hospital, Vancouver, Canada
700    1_
$a Franciosi, Sonia $u BC Children's Hospital, Vancouver, Canada
700    1_
$a Brett, Laura $u BC Children's Hospital, Vancouver, Canada
700    1_
$a Lieve, Krystien V V $u Amsterdam University Medical Center, Amsterdam, Netherlands; European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart
700    1_
$a Kwok, Sit-Yee $u Hong Kong Children's Hospital, Hong Kong, SAR China
700    1_
$a Kannankeril, Prince J $u Vanderbilt University Medical Center, Nashville, Tennessee
700    1_
$a Krahn, Andrew D $u Division of Cardiology, University of British Columbia, Vancouver, Canada
700    1_
$a LaPage, Martin J $u University of Michigan, Ann Arbor, Michigan
700    1_
$a Etheridge, Susan $u University of Utah, Salt Lake City, Utah
700    1_
$a Hill, Allison $u Children's Hospital Los Angeles, Los Angeles, California
700    1_
$a Johnsrude, Christopher $u University of Louisville, Louisville, Kentucky
700    1_
$a Perry, James $u Rady Children's Hospital, San Diego, California
700    1_
$a Knight, Linda $u Sibley Heart Center, Children's Healthcare of Atlanta, Atlanta, Georgia
700    1_
$a Fischbach, Peter $u Sibley Heart Center, Children's Healthcare of Atlanta, Atlanta, Georgia
700    1_
$a Balaji, Seshadri $u Oregon Health Science University, Portland, Oregon
700    1_
$a Tisma-Dupanovic, Svjetlana $u Nemours Children's Clinic, Orlando, Florida
700    1_
$a Law, Ian $u University of Iowa Stead Family Children's Hospital, Iowa City, Iowa
700    1_
$a Atallah, Joseph $u University of Alberta, Edmonton, Canada
700    1_
$a Backhoff, David $u University of Gottingen, Gottingen, Germany
700    1_
$a Kamp, Anna $u Nationwide Children's Hospital, Columbus, Ohio
700    1_
$a Kubus, Peter $u Motol University Hospital, Prague, Czech Republic
700    1_
$a Kean, Adam $u Indiana University School of Medicine, Indianapolis, Indiana
700    1_
$a Aziz, Peter F $u Cleveland Clinic, Cleveland, Ohio
700    1_
$a Kovach, Joshua $u Children's Hospital of Wisconsin, Milwaukee, Wisconsin
700    1_
$a Lau, Yung $u University Alabama Birmingham, Birmingham, Alabama
700    1_
$a Kron, Jordana $u Virginia Commonwealth University, Richmond, Virginia
700    1_
$a Clur, Sally-Ann $u Amsterdam University Medical Center, Amsterdam, Netherlands; European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart
700    1_
$a Sarquella-Brugada, Georgia $u European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart; Hospital Sant Joan de Déu, Barcelona, Spain
700    1_
$a Wilde, Arthur A M $u Amsterdam University Medical Center, Amsterdam, Netherlands; European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart
700    1_
$a Sanatani, Shubhayan $u BC Children's Hospital, Vancouver, Canada. Electronic address: ssanatani@cw.bc.ca
773    0_
$w MED00156180 $t Heart rhythm $x 1556-3871 $g Roč. 18, č. 11 (2021), s. 1825-1832
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34333088 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506130616 $b ABA008
999    __
$a ok $b bmc $g 1789533 $s 1163187
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 18 $c 11 $d 1825-1832 $e 20210729 $i 1556-3871 $m Heart rhythm $n Heart Rhythm $x MED00156180
LZP    __
$a Pubmed-20220425

Find record

Citation metrics

Archiving options